THALES
9.6.2020 08:02:10 CEST | Business Wire | Press release
New insights from the 2020 Thales Data Threat Report – European Edition reveal that European organisations have a false sense of security when it comes to protecting themselves, with only two-thirds (68%) seeing themselves as vulnerable, down from nine in ten (86%) in 2018. This confidence flies in the face of the findings of the survey of 509 European executives which reveals over half (52%) of organisations were breached or failed a compliance audit in 2019, raising concerns as to why a fifth (20%) intend to reduce data security spend in the next year. The findings come as workers across Europe are working from home due to COVID-19, often using personal devices which don’t have the built-in security office systems do, significantly increasing risk to sensitive data.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200608005431/en/
Thales will host a webinar, “Data Security Threats and Trends in Europe” on 16 June to discuss the report in more detail. To join, please visit the registration page .
Across the board, companies are racing to digitally transform and move more applications and data to the cloud; two-fifths (37%) of European countries stated they are aggressively disrupting the markets they participate in or embedding digital capabilities to enable greater enterprise agility. A key aspect of this transformation is in the cloud becoming the leading data environment. Nearly half (46%) of all data stored by European organisations is now stored in the cloud, and with 43% of that data in the cloud being described as sensitive, it is essential that it is kept safe.
As more sensitive data is stored in cloud environments, however, data security risks increase. This is of particular concern given that 100% of businesses surveyed report that at least some of the sensitive data they are storing in the cloud is not encrypted. Only 54% of sensitive data in the cloud is protected by encryption and even less (44%) is protected by tokenisation, highlighting the disconnect between the level of investment companies are making into cybersecurity and the increasing threats they face.
Multi-Cloud Adoption Complicates Data Security
Despite the multitude of threats, businesses feel that the complexity (40%) of their environments is holding their data security capabilities back. Multi-cloud adoption is the main driver of this complexity; four-fifths (80%) of businesses are using more than one IaaS (Infrastructure as a Service) vendor, whilst a third (29%) have more than 50 SaaS (Software as a Service) applications to manage. Businesses also identified a lack of budget (30%), staff to manage (28%) and organisation buy-in/low priority (25%) as other top blockers.
“Businesses are continuing to race towards digital transformation and many are increasingly reliant on complex cloud environments, without taking a zero-trust approach. Data is more at risk than ever, whilst organisations are unwittingly creating the perfect storm for hackers by not implementing the security basics,” commented Rob Elliss, EMEA Vice President for Data Security solutions at Thales . “Unfortunately, this will result in increasing problems, particularly in a world where working remotely will be part of the new-normal, unless companies can step up to the plate when it comes to keeping data safe.”
Quantum(fying) the problem
Whilst organisations continue to look at the threat of today, many are starting to turn their attention to peril that the acceleration of computing power, quantum, could bring to them. In fact, almost all (93%) respondents are concerned quantum computing will lead to exploits being created that could expose the sensitive data they hold. What’s more, seven in 10 (69%) European organisations expect quantum to affect their cryptographic operations in the next five years.
As a result, most organisations are reacting, with a third (31%) planning to offset quantum computing threats by switching away from static encryption or symmetric cryptography. Furthermore, a similar amount (30%) plans to implement key management that supports quantum safe random number generator.
“It is clear that businesses are aware of evolving threats they face and it’s reassuring to see them acknowledging some of the key steps they need to take – including moving away from static encryption and implementing quantum-proof key management. It’s critical, though, that organisations don’t just look at threats years away, but invest in their cybersecurity processes now and see it as an integral part of their digital transformation,” Elliss concluded .
About Thales
Thales (Euronext Paris: HO) is a global technology leader shaping the world of tomorrow today. The Group provides solutions, services and products to customers in the aeronautics, space, transport, digital identity and security, and defence markets. With 83,000 employees in 68 countries, Thales generated sales of €19 billion in 2019 (on a pro forma basis including Gemalto over 12 months).
Thales is investing in particular in digital innovations — connectivity, Big Data, artificial intelligence and cybersecurity — technologies that support businesses, organisations and governments in their decisive moments.
PLEASE VISIT
Thales Group
Market page
Download HD photos
View source version on businesswire.com: https://www.businesswire.com/news/home/20200608005431/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
OM Pharma to Unveil the Largest Multi-Country Real-World Evidence Study on Broncho‑Vaxom® (OM‑85) for RTI Prevention at EAACI 202614.6.2026 10:00:00 CEST | Press release
REACH study met its first primary endpoint, showing that Broncho‑Vaxom® (OM‑85) was associated with a 28-38% reduction in respiratory tract infection rates at 12 months and 29-41% reduction at 24 months, comparing post-treatment versus pre-treatment initiation.1 The reduction was observed regardless of the frequency of respiratory tract infections in the previous year (1-3, >3) and across age subgroups (1-5, 6-11, 12-17, 18-64, >64 years).1 By reflecting everyday clinical practice and capturing episodes that necessitated a visit to the doctor, these extensive data offer critical new evidence of the therapy’s long-term relevance for patients suffering from recurrent respiratory tract infections. Evaluating a vast cohort of more than 15,790 paediatric, adolescent, adult and elderly patients in China, Italy, and Belgium, REACH represents the largest and only multi-country real-world evidence study to date for Broncho-Vaxom®.1,2 The study cohort includes patients with different co-morbidit
Incyte Announces New Positive Data at EHA 2026 Showed INCA033989 Achieved Rapid, Robust and Sustained Clinical and Molecular Responses and Was Well Tolerated in Patients with Myelofibrosis and Essential Thrombocythemia13.6.2026 17:15:00 CEST | Press release
In myelofibrosis (MF), INCA033989 delivered rapid and durable clinical benefits including meaningful spleen volume reductions, symptom improvement and anemia responses, both as a monotherapy and in combination with ruxolitinibIn essential thrombocythemia (ET), 87% of patients achieved a hematologic response, including 70% complete responses; responses were rapid (median ~2 weeks to a durable complete hematologic response) and durable (median response duration of 23 weeks)Across MF and ET, INCA033989 consistently reduced mutant CALR (mutCALR) variant allele frequency (VAF) in most evaluable patients, with reductions correlating with clinical responses and supporting its potential for disease modificationFirst-in-class mutCALR-targeted antibody shows potential to modify disease biology in both MF and ETINCA033989 demonstrated a favorable and manageable safety profile with no dose-limiting toxicities, with most patients with MF and ET continuing treatment Incyte (Nasdaq:INCY) today announ
Results from Incyte’s Pivotal Phase 3 frontMIND Trial of Tafasitamab (Monjuvi®/Minjuvi®) Combination Presented at the 2026 European Hematology Association (EHA) Congress Plenary Showed Prolonged Progression Free Survival13.6.2026 12:00:00 CEST | Press release
- frontMIND study evaluating tafasitamab (Monjuvi®/Minjuvi®) in patients with previously untreated high-risk diffuse large B-cell lymphoma (DLBCL) and high-grade B-cell lymphoma (HGBL) selected for the prestigious Plenary Abstracts Session at EHA 2026 - Results showed tafasitamab and lenalidomide plus R-CHOP (Tafa-Len-R-CHOP) significantly prolonged progression-free survival (PFS), reducing risk of disease progression or death by 25% - Positive trends toward PFS benefit with Tafa-Len-R-CHOP were observed acrossprespecified subgroups, including in patients with centrally confirmed lymphoma subtypes and both cell-of-origin (COO) molecular subtypes - The frontMIND data support global regulatory applications for tafasitamab and lenalidomide in addition to R-CHOP for previously untreated DLBCL and HGBL Incyte (Nasdaq:INCY) today announced positive results from the pivotal Phase 3 frontMIND trial evaluating the efficacy and safety of tafasitamab (Monjuvi®/Minjuvi®), a humanized Fc-modified c
Charlotte Tilbury awarded CBE in the King’s Birthday Honours 202612.6.2026 23:31:00 CEST | Press release
Charlotte Tilbury CBE, sole Founder, President, Chairman and Chief Creative Officer of Charlotte Tilbury Beauty, has been awarded a Commander of the Order of the British Empire (CBE) in the King’s Birthday Honours 2026 for services to the beauty and cosmetics industry. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260612679101/en/ Charlotte Tilbury, founder, president, chairman and chief creative officer of Charlotte Tilbury Beauty, who has been awarded a CBE (Commander of the Order of the British Empire) in 2026 for services to the beauty industry and entrepreneurship. (Photo: Charlotte Tilbury team) This honour recognises Charlotte’s contribution to leading and building Britain’s most successful global beauty brand. She has played a defining role in revolutionising the beauty industry and driving economic growth of the UK beauty sector, which has expanded from approximately £17bn in 2013 to over £31bn today. Charlotte Til
IQM Appoints Barbara Venneman, Vanguard Board Director and Former Global Head of Deloitte Digital, to its Board of Directors12.6.2026 18:36:00 CEST | Press release
Venneman brings more than 30 years of digital transformation, AI, and enterprise technology experience as IQM prepares for its planned Nasdaq listing IQM Quantum Computers, the global leader in superconducting quantum computers, today announced the appointment of Barbara Venneman to its Board of Directors. Venneman deepens the Board's expertise in digital transformation, enterprise technology commercialization, and global business scaling as IQM expands its commercial footprint worldwide. Additionally, CEO and Co-founder Jan Goetz will replace Co-founder Juha Vartiainen as the Founder representative on the IQM Board. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260612650938/en/ IQM Appoints Barbara Venneman, Vanguard Board Director and Former Global Head of Deloitte Digital, to its Board of Directors Ms. Venneman joins the IQM Board of Directors following a distinguished career at the intersection of advanced technology, s
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
